Observational study finds GLP-1 users have increased alopecia risk compared to SGLT-2 users — Evidence Review
Published in The BMJ, by researchers from University of Pennsylvania Health System
Researched by
— the AI search engine for science
Table of Contents
A new study finds that GLP-1 medications for type 2 diabetes and obesity are linked to a slightly higher risk of hair loss, though the absolute risk remains low. Most previous research aligns with these findings, suggesting a modest but noteworthy association between GLP-1 drugs and alopecia, as detailed in this original source.
- The new results are consistent with recent studies and pharmacovigilance reports, which collectively indicate a weak to moderate association between GLP-1 receptor agonists (especially semaglutide and tirzepatide) and increased rates of hair loss, mainly non-scarring alopecia 2 4 5.
- Prior research highlights that the risk may be higher in certain populations, such as females and users of specific medications like Mounjaro, but also emphasizes that hair loss is often reversible and not always severe 1 5.
- Although some studies report isolated cases of hair regrowth, the overall evidence points toward a need for patient counseling about potential hair loss, especially given its psychological impact and effect on treatment adherence 1 3 5.
Study Overview and Key Findings
Concerns over hair loss have grown as GLP-1 receptor agonists such as Ozempic (semaglutide) and Mounjaro (tirzepatide) become increasingly popular for diabetes and weight management. While anecdotal reports and patient experiences have suggested a link between these medications and hair shedding, robust comparative research has been limited. This new study leverages electronic health records from a large academic health system to provide a quantitative assessment of alopecia risk in adults with type 2 diabetes initiating GLP-1 drugs versus alternative diabetes treatments.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | University of Pennsylvania Health System |
| Journal Name | The BMJ |
| Population | Adults with type 2 diabetes |
| Sample Size | n=12,004, n=15,221, n=11,964, n=11,233 |
| Methods | Observational Study |
| Outcome | Alopecia rates among diabetes medication users |
| Results | GLP-1 users had a 37% higher risk of alopecia than SGLT-2 users. |
The study analyzed data from over 50,000 adults with type 2 diabetes treated between January 2019 and September 2024. After adjusting for differences in age, BMI, and comorbidities, those using GLP-1 receptor agonists had a 37% higher risk of developing alopecia than those using SGLT-2 inhibitors and a 68% higher risk than those using DPP-4 inhibitors. The increased risk was primarily for non-scarring alopecia, a reversible form of hair loss. Despite the relative increase, the absolute risk remained low (about 6–7 cases per 1,000 person-years). The study could not determine severity, duration, or whether hair loss reversed after stopping the medication, and as an observational analysis, it cannot establish causality.
Literature Review: Related Studies
To place these findings in context, we searched the Consensus database, which aggregates over 200 million research papers. The following search queries were used to identify relevant studies:
- Ozempic Mounjaro hair loss risk
- GLP-1 alopecia SGLT-2 comparison
- weight loss drugs hair thinning effects
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How strong is the link between GLP-1 agonists and hair loss? | - Multiple studies and pharmacovigilance reports indicate a weak to moderate association, with semaglutide and tirzepatide showing higher reporting odds for alopecia compared to other GLP-1 drugs 2 4 5. - The observed hair loss is mainly non-scarring (telogen effluvium), and absolute risk remains relatively low 4 5. |
| Which patients are most at risk, and does the risk differ by drug? | - Female patients and those using Mounjaro (tirzepatide) may have higher risk or more severe hair loss, while the duration of drug use is less clearly linked to risk 1. - Rapid weight loss and potential nutritional deficiencies (iron, zinc) are considered contributing factors, but direct drug mechanisms remain unconfirmed 1 4 5. |
| What mechanisms might explain GLP-1-related hair loss? | - Proposed mechanisms include rapid weight loss, metabolic stress, nutrient deficiencies, and possible direct effects on hair follicles, as GLP-1 receptors are expressed in hair tissue 2 4 5. - There is some evidence for reversibility (hair regrowth) in certain cases, but the variability in outcomes and the role of glycemic control require further study 3 5. |
| Are there broader implications for clinical practice and monitoring? | - Awareness of this potential side effect may improve adherence and prevent unnecessary investigations; clinicians are advised to counsel patients and monitor hair health, especially in those with prior hair loss concerns 2 4 5. - The psychological impact of hair loss is significant, underscoring the importance of patient education and support 1. |
How strong is the link between GLP-1 agonists and hair loss?
Across multiple studies and pharmacovigilance analyses, there is a consistent—though modest—association between GLP-1 receptor agonist use and hair loss. Semaglutide and tirzepatide, in particular, are associated with elevated reporting rates of alopecia, but the absolute risk remains low. The current study’s findings of a 37–68% relative increase in risk align with these prior signals, reinforcing that while hair loss is a legitimate concern, it affects a small minority of users 2 4 5.
- Pharmacovigilance databases have reported higher-than-expected rates of alopecia among users of semaglutide and tirzepatide, with reporting odds ratios ranging from 1.24 to 2.46 4 5.
- Observational and case-control studies confirm a weak but real association; most hair loss cases are classified as non-scarring and may be reversible 5.
- Systematic reviews note that, despite the association, the majority of patients do not experience hair loss, and the effect size is generally small 2 5.
- The new study provides comparative data against other diabetes drug classes, strengthening the evidence for a drug-specific risk rather than an effect of diabetes alone 4 5.
Which patients are most at risk, and does the risk differ by drug?
Evidence suggests that risk may vary by patient characteristics and the specific GLP-1 receptor agonist used. Female patients and those treated with tirzepatide (Mounjaro) report more frequent or severe hair loss. The role of duration of therapy is unclear, but rapid weight loss and associated nutritional changes are potential contributors. The new study did not directly assess sex differences or specific subtypes but supports a class effect, especially for non-scarring alopecia 1 4 5.
- A cross-sectional study found that women and Mounjaro users have higher odds of reporting hair loss, and severity may be greater in these groups 1.
- Married patients and those with longer duration of use may also be at increased risk, though findings are less consistent 1.
- The type of GLP-1 drug may influence the risk, with semaglutide and tirzepatide associated with the highest reporting odds 4 5.
- Nutritional status (iron, zinc) and rate of weight loss are recognized risk factors for telogen effluvium, the most common type of hair loss observed 4 5.
What mechanisms might explain GLP-1-related hair loss?
The precise mechanisms underlying GLP-1 agonist-associated hair loss are not fully established. Hypotheses include rapid weight loss leading to telogen effluvium, metabolic and hormonal changes, nutritional deficiencies, and possible direct effects on hair follicles via GLP-1 receptor pathways. Some cases of hair regrowth have been reported, possibly linked to improved metabolic parameters, but the variability in outcomes remains unexplained 2 3 4 5.
- Rapid weight loss is a well-documented trigger for telogen effluvium, and GLP-1 drugs often result in significant weight reduction 4 5.
- Nutritional deficiencies (iron, zinc, vitamin D) may disrupt the hair cycle and contribute to increased shedding 4 5.
- GLP-1 receptors have been detected in murine hair follicles; whether this translates to a direct drug effect in humans remains speculative 4 5.
- Some studies document resolution or improvement of preexisting hair loss with better glycemic control, indicating a complex relationship between metabolic health and hair outcomes 3 5.
Are there broader implications for clinical practice and monitoring?
Recognizing the potential for hair loss with GLP-1 receptor agonists has practical implications for clinicians and patients. Awareness can lead to better patient counseling, informed decision-making, and avoidance of unnecessary diagnostic workups. The psychological burden of hair loss is significant for some individuals, highlighting the importance of support and monitoring, especially in patients with preexisting hair loss concerns or high cosmetic sensitivity 1 2 4 5.
- Clinicians are advised to discuss the risk of hair loss when initiating GLP-1 therapy and monitor for signs of alopecia during follow-up 2 4 5.
- Patient education can help prevent anxiety and improve adherence, especially since most cases are mild and reversible 2 4.
- Psychological distress from hair loss may affect willingness to continue therapy, particularly among women 1.
- More robust data on incidence, risk factors, and outcomes are needed to optimize patient care and develop evidence-based guidelines 1 2 4 5.
Future Research Questions
While recent studies—including the new observational analysis—have improved understanding of the association between GLP-1 receptor agonists and hair loss, important questions remain. Limitations related to causality, mechanism, patient subgroups, and long-term outcomes highlight the need for further research to guide clinical practice and patient counseling.
| Research Question | Relevance |
|---|---|
| What are the biological mechanisms linking GLP-1 agonist use and hair loss? | Clarifying mechanisms—whether related to weight loss, direct follicle effects, or nutrient deficiency—will help target prevention and management strategies and may identify modifiable risk factors 2 4 5. |
| Does hair loss reverse after discontinuing GLP-1 receptor agonists? | Understanding reversibility will inform patient counseling and expectations, especially as most reported cases are non-scarring and may resolve, but current data are limited 1 5. |
| Which patient subgroups (face higher risk) of alopecia when using GLP-1 drugs? | Identifying demographic (e.g., sex, age), clinical (e.g., BMI, comorbidities), or medication (e.g., Mounjaro vs. Ozempic) factors associated with elevated risk will help personalize therapy 1 4. |
| How does the risk of hair loss with GLP-1 compare to other weight loss or diabetes medications? | Comparative effectiveness and safety data are needed to determine whether GLP-1s confer unique risks, or whether hair loss is a feature of weight loss or metabolic improvement more generally 4 5. |
| Can nutritional supplementation reduce hair loss risk in patients on GLP-1 therapy? | If deficiencies (iron, zinc, vitamin D) contribute to hair loss, targeted supplementation could be an effective preventative or mitigating strategy, warranting clinical trials 4 5. |
This comprehensive, evidence-based overview highlights a growing body of research suggesting that GLP-1 receptor agonists—while effective for diabetes and weight loss—may be associated with a small increased risk of hair loss in some patients. Most studies, including the latest large cohort analysis, agree on the modest magnitude and generally reversible nature of this effect. Further research is needed to clarify mechanisms, identify high-risk groups, and develop targeted management strategies.